Artivion (AORT) Competitors $42.89 -0.82 (-1.88%) As of 02:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AORT vs. STVN, IRTC, GKOS, BLCO, TMDX, SLNO, NVST, LIVN, WRBY, and INSPShould you be buying Artivion stock or one of its competitors? The main competitors of Artivion include Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry. Artivion vs. Its Competitors Stevanato Group iRhythm Technologies Glaukos Bausch + Lomb TransMedics Group Soleno Therapeutics Envista LivaNova Warby Parker Inspire Medical Systems Stevanato Group (NYSE:STVN) and Artivion (NYSE:AORT) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment. Do institutionals and insiders have more ownership in STVN or AORT? 86.4% of Artivion shares are held by institutional investors. 8.1% of Artivion shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable earnings and valuation, STVN or AORT? Stevanato Group has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStevanato Group€1.19B5.91€127.45M€0.5443.19Artivion$388.54M5.21-$13.36M-$0.42-102.08 Is STVN or AORT more profitable? Stevanato Group has a net margin of 11.73% compared to Artivion's net margin of -4.43%. Stevanato Group's return on equity of 10.34% beat Artivion's return on equity.Company Net Margins Return on Equity Return on Assets Stevanato Group11.73% 10.34% 6.21% Artivion -4.43%5.70%2.29% Does the media favor STVN or AORT? In the previous week, Artivion had 4 more articles in the media than Stevanato Group. MarketBeat recorded 10 mentions for Artivion and 6 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.36 beat Artivion's score of 0.84 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artivion 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend STVN or AORT? Artivion has a consensus price target of $40.63, suggesting a potential downside of 5.23%. Given Artivion's stronger consensus rating and higher probable upside, analysts plainly believe Artivion is more favorable than Stevanato Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Artivion 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility & risk, STVN or AORT? Stevanato Group has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. SummaryStevanato Group beats Artivion on 9 of the 16 factors compared between the two stocks. Get Artivion News Delivered to You Automatically Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AORT vs. The Competition Export to ExcelMetricArtivionMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$2.03B$6.82B$5.74B$21.11BDividend YieldN/A1.19%6.66%3.50%P/E Ratio-102.2325.2382.4229.03Price / Sales5.2154.33528.3548.16Price / Cash52.6622.4425.7018.29Price / Book4.826.9110.625.29Net Income-$13.36M$176.68M$3.28B$997.87M7 Day Performance-2.01%-0.64%-0.27%-0.67%1 Month Performance38.52%3.23%10.09%6.31%1 Year Performance63.70%7.71%48.83%13.72% Artivion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AORTArtivion3.3075 of 5 stars$42.89-1.9%$40.63-5.3%+60.9%$2.02B$388.54M-102.121,600STVNStevanato GroupN/A€21.99-2.8%N/A+3.4%€6.66B€1.19B40.725,521Positive NewsIRTCiRhythm Technologies1.5835 of 5 stars$165.68-2.0%$162.64-1.8%+141.4%$5.43B$591.84M-56.552,000Positive NewsGKOSGlaukos4.7751 of 5 stars$91.78-2.5%$127.42+38.8%-29.8%$5.40B$383.48M-55.62780Positive NewsBLCOBausch + Lomb2.2143 of 5 stars$14.57-2.5%$15.56+6.8%-9.8%$5.29B$4.79B-18.6713,500Positive NewsTMDXTransMedics Group3.3138 of 5 stars$114.97-4.1%$123.00+7.0%-33.6%$4.09B$441.54M59.57210Positive NewsSLNOSoleno Therapeutics4.5579 of 5 stars$66.51-3.0%$115.09+73.0%+37.3%$3.64BN/A-16.0730Positive NewsNVSTEnvista3.7936 of 5 stars$21.15-2.6%$20.92-1.1%+13.3%$3.61B$2.51B66.1012,300News CoveragePositive NewsLIVNLivaNova1.7254 of 5 stars$56.35+0.8%$59.71+6.0%+13.0%$3.05B$1.25B-14.492,900News CoveragePositive NewsAnalyst ForecastWRBYWarby Parker1.7685 of 5 stars$26.18-3.1%$24.06-8.1%+71.6%$2.84B$771.32M-373.883,780Positive NewsINSPInspire Medical Systems4.9942 of 5 stars$93.20-2.9%$165.62+77.7%-47.4%$2.84B$802.80M53.881,246Positive NewsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies Stevanato Group Competitors iRhythm Technologies Competitors Glaukos Competitors Bausch + Lomb Competitors TransMedics Group Competitors Soleno Therapeutics Competitors Envista Competitors LivaNova Competitors Warby Parker Competitors Inspire Medical Systems Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AORT) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artivion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
